BioVector® MWCL-1 人类华氏巨球蛋白血症细胞系 / MWCL-1 Human Waldenström’s Macroglobulinemia Cell Line

通用定义 / General Definition:

BioVector® MWCL-1 是一种源自华氏巨球蛋白血症（Waldenström’s Macroglobulinemia, WM）患者外周血的 B 细胞系。该细胞系具有典型的浆细胞样差异化特征，并携带 $MYD88^{L265P}$ 突变。与 BCWM.1 相比，BioVector® MWCL-1 在表型上更接近于浆细胞阶段，是研究 WM 异质性、IgM 合成路径以及肿瘤细胞与骨髓基质相互作用的重要生物学模型。

BioVector® MWCL-1 is a B-cell line established from the peripheral blood of a patient with Waldenström’s Macroglobulinemia (WM). It exhibits distinct plasmacytoid differentiation features and carries the hallmark $MYD88^{L265P}$ mutation. Compared to BCWM.1, BioVector® MWCL-1 represents a more plasma-cell-like phenotype, making it an essential biological model for studying WM heterogeneity, IgM synthesis pathways, and the interaction between malignant cells and the bone marrow microenvironment.

BioVector® MWCL-1 细胞系技术说明书 (Cell Line Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® MWCL-1 人华氏巨球蛋白血症细胞

• 细胞来源： 人类 (Human)

• 组织来源： 外周血 (Peripheral Blood)

• 生长特性： 悬浮生长 (Suspension)

• 细胞形态： 淋巴母细胞样/浆细胞样

2. 培养条件

• 基础培养基： BioVector® RPMI 1640 培养基

• 血清添加： 10% BioVector® 胎牛血清 (FBS)

• 培养环境： 37°C，5% $CO_2$，饱和湿度

3. 细胞应用

• 疾病模型： 华氏巨球蛋白血症 (WM) 的分子机制研究。

• 信号通路： 探索 $MYD88$ 突变后的下游 TLR 信号传导。

• 药物评价： 评估蛋白酶体抑制剂或新型免疫调节药物对 WM 细胞的杀伤作用。

4. 注意事项

• 细胞密度： 为保持最佳生长状态，建议维持密度在 $4 \times 10^5$ 至 $1.5 \times 10^6$ cells/mL。

• 分化状态： 该细胞系表现出较强的浆细胞特征，实验过程中应定期监测其表面标记物（如 CD138, CD19, CD20）的表达情况。

English Datasheet

1. General Product Information

• Product Name: BioVector® MWCL-1 Human Waldenström’s Macroglobulinemia Cell Line

• Organism: Human

• Tissue Source: Peripheral Blood

• Growth Properties: Suspension

• Morphology: Lymphoblast-like / Plasmacytoid

2. Culture Conditions

• Basal Medium: BioVector® RPMI 1640 Medium

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37°C, 5% $CO_2$, Saturated Humidity

3. Applications

• Disease Modeling: Molecular mechanism studies of Waldenström’s Macroglobulinemia (WM).

• Signaling Pathways: Exploring downstream TLR signaling pathways following $MYD88$ mutation.

• Drug Evaluation: Assessing the efficacy of proteasome inhibitors or novel immunomodulatory agents against WM cells.

4. Key Usage Notes

• Culture Density: To maintain optimal growth, it is recommended to keep the cell density between $4 \times 10^5$ and $1.5 \times 10^6$ cells/mL.

• Differentiation Profile: This cell line exhibits strong plasma cell characteristics; regular monitoring of surface markers (e.g., CD138, CD19, CD20) is advised to ensure phenotypic stability.

Note: BioVector® MWCL-1 cells should be handled strictly under Biosafety Level 2 (BSL-2) guidelines. To maintain the specific metabolic profile and proliferative capacity of these malignant B-cells, the use of BioVector® RPMI 1640 Medium and BioVector® Fetal Bovine Serum is essential.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net